Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
Protocol ID
I3Y-MC-JPCS
Disease (Sub Disease)
Solid Tumours
Diagnosis Stage
Relapsed/refractory
Location
QLD, VIC, WA
Sponsor
Eli Lilly and Company
Trial Status
Closed to Recruitment
Sites
Perth Children's Hospital
Royal Children's Hospital
Queensland Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
up to 21 Years
International registry ID's
NCT04238819
Back to Registry
Study Title A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab GM-CSF Irinotecan and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
Protocol ID I3Y-MC-JPCS
Disease (Sub Disease) Solid Tumours
Diagnosis Stage Relapsed/refractory
Location QLD / VIC / WA
Sponsor Eli Lilly and Company
Links https://clinicaltrials.gov/ct2/show/NCT04238819
Trial Status Closed to Recruitment
Trial Open Date 09/11/2020
Sites Perth Children's Hospital/ Royal Children's Hospital / Queensland Children's Hospital
Study Type Treatment
Phase Phase 1/2
Age Eligibility up to 21 Years
International registry ID's NCT04238819